Thrombin Activation and Liver Inflammation in Advanced Hepatitis C Virus Infection

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2016 May 17

PMID 27182154

Citations 24

Authors

Emilio Gonzalez-Reimers

Geraldine Quintero-Platt

Candelaria Martin-Gonzalez

Onan Perez-Hernandez

Lucia Romero-Acevedo

Francisco Santolaria-Fernandez

Affiliations

Soon will be listed here.

Abstract

Hepatitis C virus (HCV) infection is associated with increased thrombotic risk. Several mechanisms are involved including direct endothelial damage by the HCV virus, with activation of tissue factor, altered fibrinolysis and increased platelet aggregation and activation. In advanced stages, chronic HCV infection may evolve to liver cirrhosis, a condition in which alterations in the portal microcirculation may also ultimately lead to thrombin activation, platelet aggregation, and clot formation. Therefore in advanced HCV liver disease there is an increased prevalence of thrombotic phenomena in portal vein radicles. Increased thrombin formation may activate hepatic stellate cells and promote liver fibrosis. In addition, ischemic changes derived from vascular occlusion by microthrombi favor the so called parenchymal extinction, a process that promotes collapse of hepatocytes and the formation of gross fibrous tracts. These reasons may explain why advanced HCV infection may evolve more rapidly to end-stage liver disease than other forms of cirrhosis.

Citing Articles

Correlation Between Thrombin Generation and Hepatic Fibrosis in Chronic Liver Diseases.

Vecerzan L, Maniu I, Cioca G Cureus. 2024; 16(10):e71376.

PMID: 39539923 PMC: 11558027. DOI: 10.7759/cureus.71376.

Hepatitis C virus infection and Parkinson's disease: insights from a joint sex-stratified BioOptimatics meta-analysis.

Narvaez-Bandera I, Suarez-Gomez D, Castro-Rivera C, Camasta-Beniquez A, Duran-Quintana M, Cabrera-Rios M Sci Rep. 2024; 14(1):22838.

PMID: 39354018 PMC: 11445468. DOI: 10.1038/s41598-024-73535-0.

Impact of Treatment with Direct Antivirals on Coagulation Parameters in Patients with Hepatitis C Virus-Related Liver Cirrhosis and Sustained Virological Response.

Huiban L, Stanciu C, Muzica C, Girleanu I, Avram R, Damian I Medicina (Kaunas). 2024; 60(9).

PMID: 39336579 PMC: 11434478. DOI: 10.3390/medicina60091539.

Interaction between coagulation and inflammatory system in liver disease: re-focus on hematological markers.

Lu L, Zhu C, Zhou D, Li S, Yi L, Wei S Biomark Med. 2024; 18(19):813-822.

PMID: 39229800 PMC: 11497986. DOI: 10.1080/17520363.2024.2395245.

Hepatic microcirculatory disturbance in liver diseases: intervention with traditional Chinese medicine.

Liu P, Liang W, Huang R, Chen X, Zou D, Kurihara H Front Pharmacol. 2024; 15:1399598.

PMID: 39108760 PMC: 11300221. DOI: 10.3389/fphar.2024.1399598.

References

Qi X, Ren W, De Stefano V, Fan D . Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014; 12(11):1801-12.e7. DOI: 10.1016/j.cgh.2014.04.026. View

Wald O, Pappo O, Safadi R, Dagan-Berger M, Beider K, Wald H . Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol. 2004; 34(4):1164-74. DOI: 10.1002/eji.200324441. View

Pinzani M, Gesualdo L, Sabbah G, Abboud H . Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest. 1989; 84(6):1786-93. PMC: 304056. DOI: 10.1172/JCI114363. View

Dahlback B . Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood. 2008; 112(1):19-27. DOI: 10.1182/blood-2008-01-077909. View

Wanless I, Liu J, Butany J . Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology. 1995; 21(5):1232-7. View

Echeverria C, Montorfano I, Tapia P, Riedel C, Cabello-Verrugio C, Simon F . Endotoxin-induced endothelial fibrosis is dependent on expression of transforming growth factors β1 and β2. Infect Immun. 2014; 82(9):3678-86. PMC: 4187819. DOI: 10.1128/IAI.02158-14. View

Feys H, Canciani M, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci P . ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol. 2007; 138(4):534-40. DOI: 10.1111/j.1365-2141.2007.06688.x. View

Adinolfi L, Giordano M, Andreana A, Tripodi M, Utili R, Cesaro G . Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol. 2001; 113(3):590-5. DOI: 10.1046/j.1365-2141.2001.02824.x. View

Giannini E, Borro P, Botta F, Fumagalli A, Malfatti F, Podesta E . Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol. 2002; 37(5):572-7. DOI: 10.1016/s0168-8278(02)00274-x. View

10.

Galli L, Gerdes V, Guasti L, Squizzato A . Thrombosis Associated with Viral Hepatitis. J Clin Transl Hepatol. 2015; 2(4):234-9. PMC: 4521234. DOI: 10.14218/JCTH.2014.00031. View

11.

Tripodi A, Primignani M, Chantarangkul V, DellEra A, Clerici M, De Franchis R . An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology. 2009; 137(6):2105-11. DOI: 10.1053/j.gastro.2009.08.045. View

12.

Marra F, Defranco R, Grappone C, Milani S, Pinzani M, Pellegrini G . Expression of the thrombin receptor in human liver: up-regulation during acute and chronic injury. Hepatology. 1998; 27(2):462-71. DOI: 10.1002/hep.510270221. View

13.

Tripodi A, Mannucci P . The coagulopathy of chronic liver disease. N Engl J Med. 2011; 365(2):147-56. DOI: 10.1056/NEJMra1011170. View

14.

Harada M, Fujisawa Y, Sakisaka S, Kawaguchi T, Taniguchi E, Sakamoto M . High prevalence of anticardiolipin antibodies in hepatitis C virus infection: lack of effects on thrombocytopenia and thrombotic complications. J Gastroenterol. 2000; 35(4):272-7. DOI: 10.1007/s005350050345. View

15.

Nagamine T, OHTUKA T, Takehara K, Arai T, Takagi H, Mori M . Thrombocytopenia associated with hepatitis C viral infection. J Hepatol. 1996; 24(2):135-40. DOI: 10.1016/s0168-8278(96)80021-3. View

16.

Wang C, Chang C, Lin C, Lin I, Kao C . Hepatitis C Virus Infection Associated With an Increased Risk of Deep Vein Thrombosis: A Population-Based Cohort Study. Medicine (Baltimore). 2015; 94(38):e1585. PMC: 4635760. DOI: 10.1097/MD.0000000000001585. View

17.

Wanless I, Shiota K . The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis. 2004; 24(1):99-106. DOI: 10.1055/s-2004-823104. View

18.

Salanova B, Choi M, Rolle S, Wellner M, Luft F, Kettritz R . Beta2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/IIIa) receptors cooperate in NF-kappaB activation of human neutrophils. J Biol Chem. 2007; 282(38):27960-9. DOI: 10.1074/jbc.M704039200. View

19.

Maharshak N, Halfon P, Deutsch V, Peretz H, Berliner S, Fishman S . Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation. World J Gastroenterol. 2011; 17(45):5007-13. PMC: 3236579. DOI: 10.3748/wjg.v17.i45.5007. View

20.

Biron C, Andreani H, Blanc P, Ramos J, Ducos J, Guigue N . Prevalence of antiphospholipid antibodies in patients with chronic liver disease related to alcohol or hepatitis C virus: correlation with liver injury. J Lab Clin Med. 1998; 131(3):243-50. DOI: 10.1016/s0022-2143(98)90096-8. View